SGMO ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Sangamo Therapeutics, Inc. investment
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...
Hosted on MSN7d
SGMO Stock Crashes as Pfizer Ends Deal for Hemophilia Candidate
Sangamo Therapeutics SGMO stock crashed 60.4% after hours on Monday after it announced that its partner, Pfizer PFE, ...
Why Is Sangamo Therapeutics Inc. (SGMO) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
Benzinga.com6d
9 Analysts Have This To Say About Sangamo Therapeutics
9 analysts have shared their evaluations of Sangamo Therapeutics SGMO during the recent three months, expressing a mix of ...
Business Wire4d
Securities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leadi…
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an ...
Sangamo Therapeutics (NASDAQ:SGMO) Given “Buy” Rating at HC Wainwright
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...
Yahoo Finance3d
PFE Returns Rights to Hemophilia A Candidate to Partner SGMO
SGMO’s stock crashed on the news. Sangamo is considering all options to continue the program, which includes looking for a new collaboration partner for the candidate. In July, the companies ...
Morningstar5d
Sangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the Company’s possible ...
Sangamo Therapeutics: Left At The Alter (Rating Downgrade)
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
Yahoo Finance3d
Sangamo Therapeutics, Inc. (SGMO)
RICHMOND, Calif., October 22, 2024--Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 ...